Preventing hepatitis C in kidney transplant recipients using antiviral pills
Part of Infections, Kidney & urinary clinical trials.
This study tests antiviral medicine given around the time of a kidney transplant to prevent hepatitis C infection when the donor has hepatitis C. It may help uninfected recipients stay hepatitis C–free after receiving the kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and meet your hospital’s usual kidney transplant (KT) criteria
- You can understand the study and sign informed consent
- You must NOT have active hepatitis C infection at screening (no detectable hepatitis C by blood test)
- You must not have cirrhosis or advanced scarring in the liver
- Your liver blood tests (AST/ALT) must not be more than 2.5 times the normal upper limit
- You cannot have HIV, active hepatitis B, or be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving newer hepatitis C medicines in a careful way to people getting a heart transplant who currently do not have hepatitis C in their blood. The goal is to lower hepatitis C infection risk from donated organs while keeping transplant outcomes safe.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new HCV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.